Do low oxytocin levels in patients with anorexia nervosa (AN) result from low weight, or do they persist even after recovery? To answer this question, this study measured oxytocin levels in women with AN, women with AN in partial recovery, and healthy controls.
What are the characteristics of individuals meeting diagnostic criteria for binge eating disorder? This report describes the characteristics of binge eating in a representative sample of adults who completed an Internet survey that included questions designed to assess binge-eating behavior in relation to DSM-5 diagnostic criteria.
Could bright light therapy be an effective intervention for eating disorders? The authors of this article conducted a review of 14 published studies of bright light therapy for eating disorders, focusing particularly on eating behavior, mood, and sleep. Read what they found out here.
Patients with binge-eating disorder experience psychiatric and somatic comorbidities and obesity, but what is the nature and magnitude of prescription medication utilization among these individuals? To answer this question, Watson and colleagues used Swedish registry data to investigate medication utilization. Read their article to find out more.
Although binge-eating disorder (BED) is the most prevalent eating disorder, it is underdiagnosed and undertreated. BED can be associated with medical and psychiatric comorbidities that, if left untreated, can impair quality of life and functionality. In this article, Kornstein and colleagues review the clinical skills needed to recognize, diagnose, and manage BED in a primary care setting.
This article describes the qualitative and quantitative research conducted to develop the 7-item Binge-Eating Disorder Screener (BEDS-7), a patient-reported screening tool designed to identify individuals with probable binge-eating disorder for further evaluation or referral.
Up to 4 million Americans have binge-eating disorder (BED). Still, little is known about the difference in health between obese and overweight people with BED in comparison to their non-bingeing counterparts. The authors of this study compared a group of overweight/obese individuals with BED to a group of overweight/obese individuals without BED to see if there were any differences in metabolic health or medication use.Â
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”